NASDAQ:FCSC - Fibrocell Science Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $1.94 -0.05 (-2.51 %) (As of 12/14/2018 03:13 PM ET)Previous Close$1.9899Today's Range$1.94 - $2.069952-Week Range$1.75 - $5.17Volume27,786 shsAverage Volume91,737 shsMarket Capitalization$18.82 millionP/E Ratio-0.24Dividend YieldN/ABeta0.85 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Fibrocell Science, Inc., an autologous cell and gene therapy company, focuses on discovering and developing therapies for diseases affecting the skin and connective tissues in the United States. The company's gene therapy product candidates include FCX-007 that is in Phase I/II clinical trials to treat recessive dystrophic epidermolysis bullosa; FCX-013, a gene therapy for localized scleroderma; and gene-therapy program that is in research phase to arthritis and related conditions. It has collaboration agreement with Intrexon Corporation for the development of FCX-007, FCX-013, and products for the treatment of chronic inflammation and degenerative diseases of human joints. The company was formerly known as Isolagen, Inc. and changed its name to Fibrocell Science, Inc. in September 2009. Fibrocell Science, Inc. was incorporated in 1992 and is based in Exton, Pennsylvania. Receive FCSC News and Ratings via Email Sign-up to receive the latest news and ratings for FCSC and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:FCSC Previous Symbol CUSIPN/A Webwww.fibrocell.com Phone484-713-6000 Debt Debt-to-Equity RatioN/A Current Ratio9.06 Quick Ratio9.06 Price-To-Earnings Trailing P/E Ratio-0.24 Forward P/E Ratio-0.51 P/E GrowthN/A Sales & Book Value Annual Sales$350,000.00 Price / Sales51.60 Cash FlowN/A Price / Cash FlowN/A Book Value$1.74 per share Price / Book1.11 Profitability EPS (Most Recent Fiscal Year)($8.25) Net Income$-16,240,000.00 Net MarginsN/A Return on Equity-177.25% Return on Assets-89.99% Miscellaneous Employees20 Outstanding Shares9,310,000Market Cap$18.82 million OptionableOptionable Fibrocell Science (NASDAQ:FCSC) Frequently Asked Questions What is Fibrocell Science's stock symbol? Fibrocell Science trades on the NASDAQ under the ticker symbol "FCSC." When did Fibrocell Science's stock split? How did Fibrocell Science's stock split work? Fibrocell Science's stock reverse split before market open on Friday, May 25th 2018. The 1-5 reverse split was announced on Thursday, May 24th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, May 24th 2018. An investor that had 100 shares of Fibrocell Science stock prior to the reverse split would have 20 shares after the split. How were Fibrocell Science's earnings last quarter? Fibrocell Science Inc (NASDAQ:FCSC) announced its earnings results on Tuesday, November, 13th. The company reported ($0.28) earnings per share for the quarter, topping the consensus estimate of ($0.83) by $0.55. View Fibrocell Science's Earnings History. When is Fibrocell Science's next earnings date? Fibrocell Science is scheduled to release their next quarterly earnings announcement on Monday, March 18th 2019. View Earnings Estimates for Fibrocell Science. What price target have analysts set for FCSC? 3 brokerages have issued 1-year price objectives for Fibrocell Science's shares. Their forecasts range from $10.00 to $22.00. On average, they expect Fibrocell Science's share price to reach $16.00 in the next twelve months. This suggests a possible upside of 724.7% from the stock's current price. View Analyst Price Targets for Fibrocell Science. What is the consensus analysts' recommendation for Fibrocell Science? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fibrocell Science in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Fibrocell Science. What are Wall Street analysts saying about Fibrocell Science stock? Here are some recent quotes from research analysts about Fibrocell Science stock: 1. HC Wainwright analysts commented, "Valuation and risks to price target achievement. We reiterate our Buy rating and $22 price target. We point out that the large delta between the current share price and our price target is driven by the company’s relatively low share count. Further, we believe that the current share price does not reflect, despite the low patient numbers, the ability of FCX-007 to address RDEB patients’ needs, as well as the accelerated potential from a regulatory standpoint, including a Priority Review Voucher (PRV)." (11/13/2018) 2. According to Zacks Investment Research, "Fibrocell Science, Inc. is an autologous cell and gene therapy company focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs. Fibrocell's most advanced drug candidate, azficel-T, uses its FDA-approved proprietary autologous fibroblast technology and is in a Phase II clinical trial for the treatment of chronic dysphonia resulting from vocal cord scarring or atrophy. In collaboration with Intrexon Corporation, a leader in synthetic biology, Fibrocell is also developing gene therapies for orphan skin diseases using gene-modified autologous fibroblasts. The Company's lead orphan gene-therapy drug candidate, FCX-007, is in late stage pre-clinical development for the treatment of recessive dystrophic epidermolysis bullosa. Fibrocell is also in pre-clinical development of FCX-013, its second gene-therapy drug candidate, for the treatment of linear scleroderma. " (10/9/2018) Has Fibrocell Science been receiving favorable news coverage? News coverage about FCSC stock has trended somewhat positive this week, according to InfoTrie. The research group scores the sentiment of press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Fibrocell Science earned a coverage optimism score of 1.1 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 4.0 out of 10, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the next several days. Who are some of Fibrocell Science's key competitors? Some companies that are related to Fibrocell Science include vTv Therapeutics (VTVT), Melinta Therapeutics (MLNT), Aridis Pharmaceuticals (ARDS), Otonomy (OTIC), KemPharm (KMPH), Checkpoint Therapeutics (CKPT), BioXcel Therapeutics (BTAI), Infinity Pharmaceuticals (INFI), Medicure (MCUJF), Oramed Pharmaceuticals (ORMP), Elite Pharmaceuticals (ELTP), Alimera Sciences (ALIM), Innovate Biopharmaceuticals (INNT), BIOLINERX LTD/S (BLRX) and NewLink Genetics (NLNK). Who are Fibrocell Science's key executives? Fibrocell Science's management team includes the folowing people: Mr. John Michael Maslowski, Pres, CEO, PFO, Principal Accounting Officer & Director (Age 43)Mr. Sean D. Buckley, VP of Bus. Admin. & Corp. Sec. (Age 36)Mr. Robert G. Partridge, VP of Global Marketing, Communications and Investor RelationsMs. Michele Mchugh-Mazzatta, VP of SalesDr. Pierre Compte, Managing Director of Switzerland Who are Fibrocell Science's major shareholders? Fibrocell Science's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (3.95%) and Virtu Financial LLC (0.53%). Company insiders that own Fibrocell Science stock include John Michael Maslowski and Randal J Kirk. View Institutional Ownership Trends for Fibrocell Science. Which institutional investors are buying Fibrocell Science stock? FCSC stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC and Virtu Financial LLC. Company insiders that have bought Fibrocell Science stock in the last two years include John Michael Maslowski and Randal J Kirk. View Insider Buying and Selling for Fibrocell Science. How do I buy shares of Fibrocell Science? Shares of FCSC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Fibrocell Science's stock price today? One share of FCSC stock can currently be purchased for approximately $1.94. How big of a company is Fibrocell Science? Fibrocell Science has a market capitalization of $18.82 million and generates $350,000.00 in revenue each year. The company earns $-16,240,000.00 in net income (profit) each year or ($8.25) on an earnings per share basis. Fibrocell Science employs 20 workers across the globe. What is Fibrocell Science's official website? The official website for Fibrocell Science is http://www.fibrocell.com. How can I contact Fibrocell Science? Fibrocell Science's mailing address is 405 EAGLEVIEW BOULEVARD, EXTON PA, 19341. The company can be reached via phone at 484-713-6000 or via email at [email protected] MarketBeat Community Rating for Fibrocell Science (NASDAQ FCSC)Community Ranking: 2.6 out of 5 ( )Outperform Votes: 200 (Vote Outperform)Underperform Votes: 191 (Vote Underperform)Total Votes: 391MarketBeat's community ratings are surveys of what our community members think about Fibrocell Science and other stocks. Vote "Outperform" if you believe FCSC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FCSC will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 12/14/2018 by MarketBeat.com StaffFeatured Article: What are Institutional Investors?